Medicxi, RA Capital join $30M round for Dutch biotech's late-stage transplantation med
Bringing Medicxi and RA Capital Management into the fold, Xenikos has clinched $30 million in Series B funding to push its transplantation med through the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
